The pharmaceutical industry's increasing focus on niche oncological markets has brought mucinous cystic neoplasms (MCNs) into sharp commercial focus. These rare pancreatic and ovarian tumors, while representing a small patient population, offer substantial revenue potential for companies willing to invest in specialized therapeutic development. The convergence of...
English
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Ελληνικά
Tiếng Việt